Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Forxiga in Patients With Type 2 Diabetes in Korea

NCT02252224 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02252224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02252224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Forxiga in Patients With Type 2 Diabetes in Korea
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
September 23, 2014
Completion date
November 30, 2016
Enrollment
3,123 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus